Sista dag i utnyttjandeperioden för teckningsoptioner av serie TO 4 B i Hamlet Pharma AB (publ) är imorgon, den 31 maj 2023
Hamlet Pharma AB (publ) (”Hamlet Pharma” eller ”Bolaget”) emitterade under 2021 teckningsoptioner av serie TO 4 B. Varje teckningsoption ger rätt att teckna en (1) ny B-aktie i Bolaget.
Teckningsperioden för teckningsoptioner av serie TO 4 B pågår från och med den 17 maj 2023 till och med den 31 maj 2023.
Notera att de teckningsoptioner som inte nyttjas senast den 31 maj 2023, förfaller värdelösa. För att teckningsoptionerna inte ska förfalla värdelösa krävs aktiv teckning av aktier. Observera att vissa förvaltare kan komma att stänga sin anmälan tidigare än den 31 maj 2023.
Fullständiga villkor för teckningsoptionerna finns att tillgå på Bolagets webbplats, www.hamletpharma.com.
Sammanfattade villkor för teckningsoptionerna av serie TO 4 B
Utnyttjandeperiod: 17 maj 2023 – 31 maj 2023.
Teckningskurs: 2,32 SEK per aktie.
Emissionsvolym: 3 943 241 teckningsoptioner av serie TO 4 B.
Vid fullt utnyttjande nyemitteras 3 943 241 B-aktier som kan tillföra upp till cirka 9,15 MSEK före emissionskostnader.
Sista dag för handel med teckningsoptioner serie TO 4 B var den 29 maj 2023.
Rådgivare
Västra Hamnen Corporate Finance AB är finansiell rådgivare samt Aqurat Fondkommission AB emissionsinstitut till Hamet Pharma i samband med utnyttjandet av teckningsoptioner av serie TO 4 B.
För mer information, kontakta
Catharina Svanborg, Styrelseordförande och grundare av Hamlet Pharma, +46 709 42 65 49, catharina.svanborg@hamletpharma.com
Martin Erixon, CEO Hamlet Pharma, +46 733 00 43 77, martin.erixon@hamletpharma.com
Hamlet Pharma AB
Hamlet Pharma is developing an entirely new class of anti-cancer therapeutics for multiple cancer indications based on the discovery of its proprietary drug complex HAMLET (‘Human Alpha-lactalbumin Made LEthal to Tumor cells’). HAMLET is derived from the human breast milk protein, alpha-lactalbumin, and represents a groundbreaking therapeutic solution with high tumor-killing capacity, high target specificity, killing >40 different types of tumor cells and no demonstrated toxicity. As such, it has the potential to revolutionize cancer treatment.
Hamlet Pharma is now advancing the second-generation drug product of HAMLET, called ‘Alpha1H’, along the clinical development pipeline as anti-cancer therapeutic for early stage bladder cancer (non-muscle-invasive bladder cancer, NMIBC). The company is focusing on NMIBC given the high clinical need for new, more effective and safe treatment options in this large growing patient group (2 million Europeans in 2023). Bladder cancer has the highest recurrence rates (70%) and treatment costs per patient among all cancer types (total costs in Europe: >€4.9 billion). Hamlet Pharma is currently testing Alpha1H in a Phase I/II clinical study in NMIBC patients.
The ongoing Phase I/II trial clearly demonstrates the competence of Hamlet Pharma and the feasibility of its approach. With the EIC SMEi Phase 2 funding, Hamlet Pharma will finalize the Phase I/II trial and the preparatory steps to enter a pivotal Phase III trial (i.e. to be ready for a licensing deal, an additional Initial Public Offer [IPO] or private investor round). Conversations with potential licensing partners and investors seeking Phase III ready products are ongoing. Alpha1H will be an important showcase of the impact HAMLET will have on cancer treatment (expected cumulative revenues: €350 million by 2027, five years after market approval). Generated revenues will be reinvested into Hamlet Pharma’s product development pipeline, ensuring further company growth.
Hamlet Pharma has started a collaboration with the company Neurochase to develop new technology and methods for the treatment of central nervous system (CNS) tumors with Alpha1H. Alpha1H is effective against a range of solid and hematological tumor cells that commonly metastasize to the CNS. Early studies in rats have shown that infusion of HAMLET into the brain markedly delayed the development of glioblastoma.